Cherry Hill, NJ, United States of America

Charles G Clark

This inventor holds 25 USPTO granted patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company. Active years: 1985-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles G Clark. Retrieved from https://idiyas.com/inventor/charles-g-clark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25

% Patents Active = 88.0

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 382(Granted Patents)

Location History:

Westland, MI (US) (1985)
Breckenridge, TX (US) (2005)
Cherry Hill, PA (US) (2008)
Cherry Hill, NJ (US) (2002 - 2021)

Company Filing History:

12 out of 3,745

Bristol-Myers Squibb Compnay

patents

9 out of 234

Bristol-Myers Squibb Pharma Company

patents

1 out of 106

Dupont Pharmaceuticals Company

patents

4. 3 out of 834,601

Other

patents

Years Active: 1985-2026

Loading Chart...

Areas of Expertise:

Factor Xa Inhibitors

Thrombin Inhibitors

Peptide Agonists

Triazolopyridine

Cyclic P1 Linkers

Guanidine Compounds

Tetrahydroisoquinoline

Nitrogen Containing Heterobicycles

Pyrazolobenzamides

Ullmann Coupling

Variable Resistance Exercise

Pharmaceutical Chemistry

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577206 - Pyrazolone formyl peptide 2 receptor agonists (2026-03-17),

2. 11008317 - Triazolopyridine inhibitors of myeloperoxidase and/or EPX (2021-05-18),

3. 9428504 - [object Object] (2016-08-30),

4. 9403774 - Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors (2016-08-02),

5. 9315519 - Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors (2016-04-19),

6. 9108981 - Cyclic P1 linkers as factor XIa inhibitors (2015-08-18),

7. 8901115 - Cyclic P1 linkers as factor XIa inhibitors (2014-12-02),

8. 7960569 - [object Object] (2011-06-14),

9. 7674828 - [object Object] (2010-03-09),

10. 7388021 - [object Object] (2008-06-17),

11. 7381732 - Pyrazolobenzamides and derivatives as factor Xa inhibitors (2008-06-03),

12. 7235575 - Guanidine mimics as factor Xa inhibitors (2007-06-26),

13. 6958356 - Guanidine mimics factor Xa inhibitors (2005-10-25),

14. 6906070 - Guanidine mimics as factor Xa inhibitors (2005-06-14),

15. 6858616 - Nitrogen containing heterobicycles as factor Xa inhibitors (2005-02-22),

Title: Unveiling the Innovation Journey of Inventor Charles G Clark

Introduction: Meet Charles G Clark, an inventive mind hailing from Cherry Hill, NJ, with a remarkable portfolio of 24 patents under his belt.

Latest Patents: Among his recent creations are Triazolopyridine inhibitors targeting myeloperoxidase (MPO) and/or eosinophil peroxidase (EPX), designed to combat conditions like atherosclerosis, heart failure, and COPD. Additionally, his work includes compounds as P2Y receptor antagonists for treating thromboembolic disorders.

Career Highlights: Charles G Clark has made substantial contributions to the field through his tenure at esteemed companies like Bristol-Myers Squibb Company and Bristol-Myers Squibb Pharma Company, where his innovative spirit shone bright.

Collaborations: Throughout his career, Charles collaborated with industry experts such as Donald J P Pinto and Patrick Y S Lam, pooling their knowledge and skills to drive forward groundbreaking developments in medicine and pharmaceuticals.

Conclusion: Charles G Clark's dedication to innovation and relentless pursuit of cutting-edge solutions have undoubtedly left an indelible mark on the landscape of patents and inventions, solidifying his position as a trailblazer in the field.

Profile summary based on public USPTO records.